| 14 Décembre 2010
In addition to trading on the NASDAQ, Pluristem's ordinary shares to begin trading on TASE under ticker symbol PLTR starting December 19, 2010
- Company Anticipates Joining four of TASE’s Indexes
- Pluristem will open trading on the TASE on December 19 and will host a welcoming ceremony for investors and a press conference for journalists following the market opening
HAIFA, ISRAEL, December 12, 2010 -- Pluristem Therapeutics Inc. (NasdaqCM: PSTI), today announced that the Tel-Aviv Stock Exchange (“TASE”) has approved the dual listing of the Company’s ordinary shares on the TASE beginning at market open on December 19, 2010, under the ticker symbol PLTR.
The Company also announced today that, based upon Pluristem's current market capitalization, it expects its shares to be subject to inclusion in four TASE equity indexes: Tel-Tech, TA Composite, MidCap TA and Biomed.
"Pluristem is very proud to be listing its shares on the TASE, allowing us to address the great interest among local institutional investors and strategic partners to our solutions and technology platform," said Zami Aberman, CEO of Pluristem. "Listing on the TASE is an important part of the Company's vision of growing the Israeli economy through the country's pharmaceutical industry, and while Pluristem is the first stem-cell company to list on the TASE, we look forward to being joined by other companies in the near future."
Mr. Aberman; Prof. Edwin Horwitz, President of the International Society for Cellular Therapy and Chairman of Pluristem's Scientific Advisory Board; and Mr. Jason Kolbert, senior biotechnology analyst and Managing Director at National Securities, will speak at an investors conference following the market opening and will be available to answer questions.
In September 2010, Pluristem reported that data from clinical trials show the Company’s placenta-derived cell therapy, PLX-PAD, is potentially safe and improves quality of life as well as other efficacy measurements in patients with Critical Limb Ischemia (CLI), the end-stage of Peripheral Artery Disease (PAD).
"Following the successful conclusion of Phase 1 testing, Pluristem invested heavily in upgrading its research and development laboratories in Haifa in order to equip them properly for future clinical trials," added Mr. Aberman. "Looking ahead, we plan to build a state of the art development facility that will allow Pluristem to produce large quantities of therapeutics at the highest quality levels, enabling the company to provide relief to millions of patients around the world."
"We congratulate Pluristem on joining the Tel Aviv Stock Exchange," said Ester Levanon, CEO of the TASE. "The biomed sector is one of the fastest growing industries in Israel and with over 50 biomed companies currently traded, the TASE has become one of the world's leading exchanges for biomed companies to list on. A dual listing on the NASDAQ and TASE provides companies such as Pluristem with numerous advantages, including greater exposure to Israeli institutional investors, a longer trading day and access to funds that follow the TASE."
Pluristem is, and plans to remain, subject to the applicable rules and regulations of NASDAQ-listed companies and the U.S. Securities and Exchange Commission. Under Israel ’s Dual Listing Law, U.S.-listed companies may dual-list on the TASE without any additional regulatory requirements. Trading on the TASE occurs Sunday through Thursday from 8:30 am to 4:30 pm Israel time, except on TASE trading holidays. The TASE Clearing House is electronically linked to the Depository Trust Company, a subsidiary of the Depository Trust & Clearing Corporation, to automate the cross-border settlement of shares listed on both the TASE and a U.S. Exchange.
